Updates for BTK Inhibitors in CLL Around ASH 2024

Experts detail updates regarding BTK inhibitors in chronic lymphocytic leukemia around the 2024 ASH Annual Meeting.

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

ByAlexey V. Danilov, MD, PhD,Susan M. O'Brien MD

December 31st 2024

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

ByMazyar Shadman, MD, MPH

December 19th 2024

Dr Shadman discusses key findings and implications from trials that were presented at the 2024 ASH Annual Meeting investigating zanubrutinib in CLL.

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

ByAlexey V. Danilov, MD, PhD,Nicole Lamanna, MD

November 25th 2024

Drs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.

Updates for BTK Inhibitors in CLL Around ASH 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Trending on OncLive

FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma

Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC

ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care

Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD

Dr Borate on Efficacy Data for Shorter Venetoclax-Plus-Azacitidine Dosing in AML